Spindle cell rhabdomyosarcomas: With TFCP2 rearrangements, and novel EWSR1::ZBTB41 and PLOD2::RBM6 gene fusions. A study of five cases and review of the literature

Abstract

AimsSpindle‐cell/sclerosing rhabdomyosarcomas (SS‐RMS) are clinically and genetically heterogeneous. They include three well‐defined molecular subtypes, of which those with EWSR1/FUS::TFCP2 rearrangements were described only recently. This study aimed to evaluate five new cases of SS‐RMS and to perform a clinicopathological and statistical analysis of all TFCP2‐rearranged SS‐RMS described in the English literature to more comprehensively characterize this rare tumour type.Methods and ResultsCases were retrospectively selected and studied by immunohistochemistry, fluorescence in situ hybridization with EWSR1/FUS and TFCP2 break‐apart probes, next‐generation sequencing (Archer FusionPlex Sarcoma kit and TruSight RNA Pan‐Cancer Panel). The PubMed database was searched for relevant peer‐reviewed English reports. Five cases of SS‐RMS were found. Three cases were TFCP2 rearranged SS‐RMS, having FUSex6::TFCP2ex2 gene fusion in two cases and triple gene fusion EWSR1ex5::TFCP2ex2, VAX2ex2::ALKex2 and VAX2intron2::ALKex2 in one case. Two cases showed rhabdomyoblastic differentiation and spindle‐round cell/sclerosing morphology, but were characterized by novel genetic fusions including EWSR1ex8::ZBTB41ex7 and PLOD2ex8::RBM6ex7, respectively. In the statistical analysis of all published cases, CDKN2A or ALK alterations, the use of standard chemotherapy and age at presentation in the range of 18–24 years were negatively correlated to overall survival.ConclusionEWSR1/FUS::TFCP2‐rearranged SS‐RMS is a rare rhabdomyosarcoma subtype, affecting predominantly young adults with average age at presentation 34 years (median 29.5 years; age range 7–86 years), with a predilection for craniofacial bones, rapid clinical course with frequent bone and lung metastases, and poor prognosis (3‐year overall survival rate 28%).